• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

79.90 EUR+2.50 %13.8. klo 18.29
14,468 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.50 %
+14.72 %
+18.63 %
+18.90 %
+25.53 %
+20.06 %
+124.25 %
+129.60 %
+611.49 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
11.28B EUR
Turnover
13.1M EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
20.07.2026
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Thanks for the great question! The short answer is that I agree regarding the uncertainty/risk in pricing, and it has been accounted for by being conservative in our forecasts. Here is a slightly longer version and a few comments: I would point out here that the highest royalty tier...
7/22/2026, 7:21 AM
by Antti Siltanen
18
Here is Liisa’s interview for a summery Friday. 00:00 Q2 in brief 00:44 Divina 02:10 Easyhaler 02:55 Generic medicines 04:39 Tessie 06:25 LEVEL study 07:55 Net cash position (Net debt-free balance sheet) 09:53 Guidance upgrade I referred to the ROAST a couple of times, here is a ...
7/17/2026, 12:43 PM
by Verneri Pulkkinen
13
There are certainly many moving parts here, but generic enzalutamide is no longer just a future possibility. In the EU, Xtandi’s patent protection expires this year, and Enzalutamide Viatris already received marketing authorization in 2024. Meanwhile, in the US, the FDA has approved...
7/21/2026, 1:41 PM
by Juho R
6
Antti’s report provided a good breakdown of where this year’s strong results are coming from. Nubeqa royalties grew by 80%, and the highest royalty tier was reached as early as Q2. However, this brings to mind one question regarding longer-term forecasts. Now that the highest royalty...
7/21/2026, 11:43 AM
by Juho R
6
Inderes Orionin lisenssikumppani Tenax Therapeuticsin Faasi 3 LEVEL-tutkimus... ORION OYJ PÖRSSITIEDOTE – SISÄPIIRITIETO 10.8.2026 KLO 14.05 Orionin lisenssikumppani Tenax Therapeuticsin Faasi 3 LEVEL-tutkimus oraalisella levosimendaanilla sydämen vajaatoiminnasta johtuvan... So,...
8/10/2026, 11:17 AM
by veronmaksaja
5
Antti has written a company report on Orion following Q2 Inderes Orion Q2'26: Huipputuloksessa mukana kertaluonteista myötätuulta - Inderes Myynnin kasvu ja rojaltiprosentin nousu tukivat vahvaa neljännestä.
7/20/2026, 6:07 AM
by Sijoittaja-alokas
5
Here are Antti’s comments on the fact that Orion’s licensing partner Tenax Therapeutics’ phase 3 study did not meet its primary endpoint. Inderes – 11 Aug 26 Orion: Takaisku levosimendaanin faasi 3 -tutkimuksessa - Inderes Pidämme aihion tietä myyntilupaan epätodennäköisenä.
8/11/2026, 8:15 AM
by Sijoittaja-alokas
4
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.10.
2026

Half year dividend

28.10.
2026

Interim report Q3'26

17.2.
2027

Annual report '26

Regulatory press release10.08.2026 klo 14.05

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

Orion
Orion, Webcast, Q2'26
Webcast17.07.2026 klo 14.00

Orion, Webcast, Q2'26

Orion
Regulatory press release17.07.2026 klo 12.00

Orion Group Half-Year Financial Report January–June 2026

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release17.07.2026 klo 10.30

Orion Corporation’s financial reporting and Annual General Meeting in 2027

Orion
Regulatory press release15.07.2026 klo 09.00

45,611 Orion Corporation A shares converted into B shares

Orion
Press release03.07.2026 klo 09.00

Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026

Orion
Press release30.06.2026 klo 08.00

Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market

Orion
Press release23.06.2026 klo 09.30

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

Orion
Regulatory press release18.06.2026 klo 14.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release17.06.2026 klo 16.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release16.06.2026 klo 16.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release15.06.2026 klo 16.15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release11.06.2026 klo 17.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release10.06.2026 klo 18.10

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release05.06.2026 klo 17.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release01.06.2026 klo 14.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Press release30.05.2026 klo 21.30

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

Orion
Press release21.05.2026 klo 10.30

Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting

Orion
Regulatory press release15.05.2026 klo 09.00

105,950 Orion Corporation A shares converted into B shares

Orion
Press release12.05.2026 klo 10.30

Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs

Orion